Rybelsus vs Mounjaro

Rybelsus and Mounjaro are FDA-approved for type 2 diabetes and widely used off-label for weight management, but monthly prices can exceed $900 without insurance.

Studies show Mounjaro users lose up to 22% of body weight, while Rybelsus averages around 9-12%. However, differences in injection vs. oral use, tolerability, and long-term sustainability can make the choice confusing.

In this article, we’ll break down Rybelsus vs. Mounjaro, including how they work, what users actually experience, and which might suit your health goals best. Let’s find which may be the smarter fit for you.

Which is more effective, Rybelsus or Mounjaro?

There haven’t been any direct, head-to-head studies comparing oral semaglutide (Rybelsus) and tirzepatide (Mounjaro) yet. Most available data involve injectable semaglutide (Ozempic or Wegovy) versus tirzepatide.

But both drugs have been proven to improve blood sugar control in people with type 2 diabetes. Mounjaro was evaluated in the SURPASS clinical program, while Rybelsus was studied in the PIONEER program.

For Type 2 Diabetes

In the SURPASS-2 trial, patients treated with Mounjaro experienced up to a 2.3% decrease in HbA1c, compared with a 1.86% decrease in those taking 1 mg of injectable semaglutide.

Across the SURPASS program, many participants reached normal blood sugar levels below 5.7%. Mounjaro treatment also improved weight, blood pressure, and cholesterol without increasing the risk of hypoglycemia.

In the PIONEER trials, once-daily Rybelsus 14 mg lowered HbA1c by 1-1.5%. This was greater than the reductions seen with sitagliptin and empagliflozin and similar to liraglutide after 26 to 52 weeks.

In PIONEER PLUS, which used higher doses of oral semaglutide at 25 and 50 mg, results showed HbA1c reductions of 1.8-2.0%, compared with 1.5% at 14 mg.

These results suggest that Mounjaro may deliver stronger blood sugar improvements, especially for people who have struggled to reach their targets with other diabetes medications.

For Weight Loss

A real-world US study comparing tirzepatide and injectable semaglutide found that tirzepatide users were 76 % more likely to lose at least 5% of body weight and over three times more likely to lose at least 15%.

Tirzepatide outperformed injectable semaglutide by:

• • 2.5 kg (~6 lb) at 3 months
  • 4.7 kg (~10 lb) at 6 months
  • 7.6 kg (~17 lb) at 12 months

Another real-world study showed that tirzepatide users lost 8-10 kg (~17-22 lb) on average across both treatment-naïve and previously treated populations, compared with 4-6 kg (~8-13 lb) with injectable semaglutide.

In the PIONEER program, Rybelsus produced 2-5 kg (~4.5-11 lb) of weight loss depending on dose and background therapy. In PIONEER PLUS, higher doses achieved 6.7-8.0 kg ~15-17.6 lb) reductions, comparable to results from the STEP 2 trial of injectable semaglutide 2.4 mg (Wegovy).

Note that these higher oral semaglutide doses are not yet approved. The FDA is expected to announce whether it will approve the oral form by the end of 2025. If approved, it would be the first oral GLP-1 treatment for obesity.

Mounjaro’s advantage has been consistent in both randomized trials and real-world data, even when accounting for dose escalation or prior GLP-1 use.

Even if Rybelsus eventually becomes available in higher doses, Mounjaro is still expected to produce greater average weight loss overall. Still, both remain highly effective options for diabetes and metabolic improvement.

Which causes more side effects?

In separate placebo-controlled studies, side effects of Mounjaro and Rybelsus included gastrointestinal symptoms such as:

Other gastrointestinal side effects observed with both Rybelsus and Mounjaro include:

• • Eructation (belching)
  • Abdominal distension (bloating)
  • Flatulence
  • Gastroesophageal reflux disease (GERD)
  • Abdominal distension
  • Gastritis

A slightly higher proportion of participants stopped treatment because of digestive side effects with Rybelsus at higher doses. About 8% discontinued at the 14 mg dose and 4% at the 7 mg dose, compared with 5.4% and 6.6% for Mounjaro at the 10 mg and 15 mg doses, respectively.

Both Rybelsus and Mounjaro can also pose other potential risks, including:

• • Acute pancreatitis
  • Diabetic retinopathy
  • Hypoglycemia
  • Acute kidney injury
  • Risk of thyroid C-cell tumors
  • Acute gallbladder disease
  • Pulmonary aspiration during general anesthesia or deep sedation
  • Hypersensitivity

How do Rybelsus and Mounjaro work?

Rybelsus is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the natural GLP-1 hormone, which regulates glucose metabolism by increasing insulin release after meals, slowing the rate at which food leaves the stomach, and decreasing appetite. Through these actions, Rybelsus helps lower blood sugar levels and promotes weight loss.

Mounjaro is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP is another incretin hormone that stimulates insulin secretion and may improve insulin sensitivity.

By targeting both GLP-1 and GIP receptors, Mounjaro offers a broader approach to blood sugar control. This dual activity enhances insulin response, reduces insulin resistance, and produces greater average weight reduction compared with single-pathway GLP-1 agents such as Rybelsus.

What are they used for?

Both Rybelsus and Mounjaro are approved to improve blood sugar control in adults with type 2 diabetes when used along with diet and exercise. Rybelsus also carries an additional indication for reducing the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have established cardiovascular disease.

Mounjaro does not currently have this cardiovascular risk reduction approval. Its long-term cardiovascular effects are still being investigated in the SURPASS-CVOT study.

How are Rybelsus and Mounjaro dosed?

Mounjaro is injected once weekly. Treatment begins with 2.5 mg once a week for the first four weeks, then increases to 5 mg weekly for at least the next four weeks. If additional blood sugar control is needed, the dose may be increased in 2.5 mg steps after at least four weeks on the current level, up to a maximum of 15 mg once weekly.

On the other hand, Rybelsus is taken by mouth once daily in the morning on an empty stomach with no more than 4 ounces (about half a cup) of water.

After swallowing the tablet, wait at least 30 minutes before eating, drinking, or taking any other medications. The tablet should be swallowed whole, not split, crushed, or chewed.

Here is the typical Rybelsus dosing schedule:

Cost of Rybelsus vs. Mounjaro 

Rybelsus and Mounjaro remain costly for uninsured patients, priced at $997.58 and $1,079.77 per package, respectively.

Pharma Giant provides a lower-cost and convenient alternative for getting these treatments. As a licensed Canadian pharmacy partner, Pharma Giant offers safe, verified medications at prices often below US retail costs, with direct home delivery for added convenience.

Here’s a look at the pricing and savings with Rybelsus from Pharma Giant:

Here’s a look at the pricing and savings with Mounjaro Kwikpens from Pharma Giant:

Here’s a look at the pricing and savings with Mounjaro vials from Pharma Giant:

You can save even more with our Mounjaro coupons and Rybelsus coupons, and as a new customer, you’ll get an extra 10% off with the code PGSAVE10.

Note: Eli Lilly Canada supplies Mounjaro in two formats. The Mounjaro KwikPen is a multi-dose, single-patient prefilled injection pen. Each pen delivers four weekly doses, so one pen lasts an entire month. Meanwhile, the Mounjaro vial is a single-dose format, meaning each vial contains one full dose. A typical month of treatment requires four vials. However, availability is becoming limited, as most patients and pharmacies have transitioned to the newer KwikPen delivery system.

Summary

Rybelsus and Mounjaro are both effective for type 2 diabetes, but they work differently. Rybelsus is an oral semaglutide tablet taken daily, while Mounjaro is a once-weekly injectable that targets both GLP-1 and GIP receptors for stronger blood sugar and weight loss results.

Studies show Mounjaro lowers HbA1c and body weight more than semaglutide, though both drugs improve glucose control and support weight loss. Rybelsus is more convenient if you prefer pills, while Mounjaro may deliver faster, more consistent results.

Both can cause nausea, diarrhea, and appetite loss, but most side effects improve over time. Cost is a major factor, and both are expensive in the US, though Pharma Giant offers much lower pricing for both options.

Always consult your healthcare provider before switching or starting any diabetes medication. The best choice depends on your medical history, tolerance, and comfort with injections versus tablets.

Frequently Asked Questions

Sources

Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023). Achieving normoglycemia with tirzepatide: Analysis of SURPASS 1–4 trials. Diabetes Care, 46(11), 1986–1992. https://doi.org/10.2337/dc23-0872

Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519

Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525

Hoog, M. M., Vallarino, C., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K., & Richard, E. L. (2025). Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-025-01794-9

Zargar, A., Kalra, S., & Das, S. (2022). A review of oral semaglutide available evidence. Indian Journal of Endocrinology and Metabolism, 26(2), 98–105. https://doi.org/10.4103/ijem.ijem_522_21

Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023). Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. The Lancet, 402(10403), 693–704. https://doi.org/10.1016/s0140-6736(23)01127-3

PR Newswire. FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity. https://www.prnewswire.com/news-releases/fda-accepts-filing-application-for-oral-semaglutide-25-mg-which-if-approved-would-be-the-first-oral-glp-1-treatment-for-obesity-302445232.html

Mounjaro Cost Information | With or Without Insurance | Mounjaro® (tirzepatide) injection. (n.d.). https://pricinginfo.lilly.com/mounjaro

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg List Price & Insurance Coverage Explained | NovoCare®. (n.d.). https://www.novocare.com/diabetes/products/rybelsus/explaining-list-price.html